Van Leeuwenhoeck's view on the market 

The life sciences industry is evolving rapidly. Many say it's at the beginning of an explosive growth stage that will see the development and commercialization of novel therapeutics and diagnostics still being imagined in scientific laboratories today. This explosion of innovation also means an explosion of investment opportunity. In this interview with The Life Sciences Report, Marcel Wijma, managing director at Van Leeuwenhoeck Institute, explores some smaller companies working on the industry's forefront. 

Galapagos (GPLG.BR): Research Note 

Galapagos announced that its JAK1 inhibitor filgotinib (GLPG0634) met its primary and secondary endpoints after 12 weeks of treatment in the socalled DARWIN in moderate to severe RA patients 

uniQure (QURE): Research Note 

uniQure surprised with the news that it has entered into an agreement with Bristol Myers Squibb (BMY) that provides BMY exclusive access to its gene therapy platform for multiple targets in cardiovascular diseases. 

Resverlogix (RVX.TO): Initiating Coverage Report 

Resverlogix is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. The company is the first to test the BET inhibition hypothesis as a new approach for reducing major adverse cardiovascular events (MACE) in high risk diabetes and CKD patients.

Latest Research

an unbiased and independent view on companies in the global life sciences sector

Van Leeuwenhoeck Institute (VLI) provides institutional investors and other professional investors with independent, un-biased research on the real value of innovative Life Sciences companies. Many institutional and individual investors will not invest in companies lacking independent third-party research coverage, yet few investment banks cover this sector because it requires dedicated expertise.

In spite of the lack of quality knowledge on an industry-wide basis, there is increased demand for life science-specific market research as investors are seeking information about leading companies in the sector in order to make well-informed investment decisions.


Invion Group (INV.AX): Research Note 

Invion Group is an Australian based biotech company focused on the development of treatments for large indications in respiratory disease and autoimmune disease. The company has three drug assets in development, with three FDA-regulated, phase II clinical trials and two preclinical feasibility studies currently ongoing. 

antonie van leeuwenhoek

(delft, netherlands 1632-1723):

founding father of modern biotechnology

We are proud our firm is named after one of the founding fathers of modern biotechnology: Antonie van Leeuwenhoek. Antonie van Leeuwenhoek was a Dutch scientist that lived in the 17th century: 'The Dutch Golden Age", a period in Dutch history, roughly spanning the 17th century, in which Dutch trade, science, military, and art were among the most acclaimed in the world. He was a Dutch tradesman and scientist and is commonly known as "the Father of Microbiology", and considered to be the first microbiologist.

He is best known for his work on the improvement of the microscope and for his contributions towards the establishment of microbiology. Using his handcrafted microscopes, he was the first to observe and describe single-celled organisms, which he originally referred to as animalculs,and which are now referred to as micro organisms. He was also the first to record microscopic observations of muscle fibers, bacteria, spermatozoa, and blood flow in capillaries (small blood vessels). Leeuwenhoek did not author any books; his discoveries came to light through correspondence with the Royal Society, which published his letters.


Pharmaxis (PXS.AX): Research Note 

Pharmaxis is an Australian based pharmaceutical company with a portfolio of products at various stages of development and approval. Recently the company announced its new strategy that is focused on innovation and partnering. A very successful example of implementing this strategy was already announced last week when the company published that Boehringer Ingelheim has exercised its option to acquire the investigational drug PXS4728A, to develop it for the treatment of the liver‐related condition NASH and to prevent its consequences.